{"result": "(\"entity\"<|>NUTRICIÓN ARTIFICIAL<|>EVENT<|>Nutrición artificial refers to the provision of nutrients through means other than oral intake, often used in patients who cannot eat normally, and can impact fluid and electrolyte balance.)\n##\n(\"entity\"<|>DIURÉTICOS<|>ORGANIZATION<|>Diuréticos are medications that promote the excretion of water and salts from the body, commonly used in the treatment of conditions like hiponatremia and insuficiencia cardiaca.)\n##\n(\"entity\"<|>SODIO<|>ORGANIZATION<|>Sodio is an essential electrolyte in the body that helps regulate fluid balance, and its levels are critical in the management of hiponatremia.)\n##\n(\"entity\"<|>HIDROCORTISONA<|>ORGANIZATION<|>Hidrocortisona is a corticosteroid medication used to treat various conditions, including adrenal insufficiency, and may be relevant in the context of managing fluid balance in patients.)\n##\n(\"relationship\"<|>NUTRICIÓN ARTIFICIAL<|>HIPONATREMIA<|>Nutrición artificial can influence sodium levels and fluid balance, potentially leading to or exacerbating hiponatremia<|>6)\n##\n(\"relationship\"<|>DIURÉTICOS<|>HIPONATREMIA<|>Diuréticos are often used to treat hiponatremia by promoting the excretion of excess fluid and helping to correct sodium levels<|>8)\n##\n(\"relationship\"<|>SODIO<|>HIPONATREMIA<|>Sodio levels are critical in diagnosing and treating hiponatremia, as low sodium is the defining characteristic of the condition<|>10)\n##\n(\"relationship\"<|>HIDROCORTISONA<|>INSUFICIENCIA CARDIACA<|>Hidrocortisona may be used in patients with insuficiencia cardiaca to manage associated conditions, including fluid retention<|>5)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: ología; respetando también los límites de incremento máximo de natremia, previamente citados³⁹, ⁴⁵. El objetivo principal de este tratamiento es alcanzar y mantener la eunatremia; si no es posible, evitar al menos el empeoramiento de la hiponatremia y el desarrollo de una hiponatremia grave.\n\n### 5.2.1. Tratamiento de la hiponatremia hipovolémica\n\nEl primer y principal paso en la hiponatremia hipovolémica es reponer la volemia, consiguiendo así inhibir la secreción de ADH inducida por el estímulo barorreceptor. En los pacientes con NE, se puede realizar mediante la administración de solución salina isotónica (SFS al 0,9%), al igual que en los pacientes sin nutrición artificial. Sin embargo, en aquellos con NP se puede expandir el volumen plasmático, bien añadiendo SSF al 0,9% o aumentando de forma isotónica el volumen de la NP con el incremento del aporte de sodio y líquidos (disminuir la concentración de la glucosa y utilizar una mezcla más diluida de aminoácidos). A las 24-48 horas del inicio del tratamiento, este debe modificarse en función de la restauración de la volemia y de la elevación de la natremia.\n\nEn algunos casos de hiponatremia hipovolémica como la asociada a diuréticos, además de reponer la volemia se debe retirar el fármaco. Así como en los pacientes con insuficiencia suprarrenal primaria es necesario pautar hidrocortisona (20 mg/8 h por SNG o 150-200 mg intravenosa en perfusión continua/24 h) y en los pacientes con hipoaldosteronismo se debe retirar el fármaco causante (IECA, espironolactona, amiloride, AINE). En estos últimos, ocasionalmente será necesario asociar fludrocortisona (0,05 a 0,10 mg/día) al tratamiento, sobre todo si se debe a un fármaco que no puede suspenderse inicialmente (por ejemplo, la heparina)³⁹.\n\n### 5.2.2. Tratamiento de la hiponatremia hipervolémica\n\nLos pacientes con insuficiencia cardiaca son tratados inicialmente con la terapia convencional, que consta de la disminución del consumo de sal, restricción de líquidos, furosemida y bloqueo SRAA. La finalidad de este tratamiento es aumentar el volumen circulante efectivo (disminución de la postcarga con el bloqueo del SRAA y la precarga con la furosemida), inhibiendo así el estímulo barorreceptor de la ADH. A pesar de esta terapia, en los pacientes con hiponatremia no se alcanza la normonatremia. Probablemente, a consecuencia de la resistencia a la acción de la furosemida que ocurre cuando el consumo de sal es bajo⁶⁷. De hecho, se ha objetivado una respuesta eficaz y segura tras la administración de un aporte significativo de sodio (perfusión de solución salina hipertónica) acompañado de dosis altas de furosemida⁶⁸. En estos casos de hiponatremia refractaria, los antagonistas del receptor V2 de la vasopresina (tolvaptán o conivaptán) también consiguen una corrección de la hiponatremia. Además de una mejoría significativa de la clínica, una disminución de la mortalidad y de la tasa de reingreso⁶⁹. El uso de estos fármacos para el tratamiento de hiponatremia en pacientes con insuficiencia cardiaca únicamente está aprobado en EEUU. Por lo tanto, en pacientes con nutrición artificial, además del tratamiento diurético y bloqueo neurohormonal, será conveniente disminuir el aporte de líquidos (concentrar la fórmula de NP si es posible y utilizar fórmulas hipercalóricas en NE) y asegurar un aporte mínimo de 7,5-8 g de ClNa (128-136 mEq de sodio), garantizando así la acción terapéutica de la furosemida.\n\nEn los pacientes cirróticos con descompensación hidrópica e hiponatremia, los principios básicos del tratamiento son similares a los previamente descritos para la insuficiencia cardiaca. Salvo alguna puntualización como la administración conjunta de albúmina (a corto plazo), la paracentesis y la retirada o disminución de la dosis de espironolactona en el caso de hipoaldosteronismo⁴⁵. La actitud a tomar durante la administración\n---\nTema 51. Metabolismo hídrico en los pacientes con nutrición artificial... 809\n\nde la nutrición artificial es la misma que en los pacien-\ntes con ICCA e hiponatremia.\n\n### 5.2.3. Tratamiento de la hip\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>HIPONATREMIA<|>EVENT<|>Hiponatremia is a medical condition characterized by low sodium levels in the blood, which can lead to various health complications and requires specific treatment protocols.)\n##\n(\"entity\"<|>INSUFICIENCIA CARDIACA<|>EVENT<|>Insuficiencia cardiaca is a medical condition where the heart is unable to pump sufficiently to maintain blood flow to meet the body's needs, often leading to fluid retention and other complications.)\n##\n(\"entity\"<|>FUROSEMIDA<|>ORGANIZATION<|>Furosemida is a diuretic medication used to treat fluid build-up due to heart failure, liver scarring, or kidney disease, and is often part of the treatment for hiponatremia.)\n##\n(\"entity\"<|>ALBUMINA<|>ORGANIZATION<|>Albúmina is a protein in the blood that helps maintain blood volume and pressure, and is sometimes administered in patients with cirrhosis and fluid retention.)\n##\n(\"entity\"<|>TOLVAPTÁN<|>ORGANIZATION<|>Tolvaptán is a medication that acts as a vasopressin receptor antagonist, used to treat hyponatremia, particularly in patients with heart failure.)\n##\n(\"entity\"<|>CONIVAPTÁN<|>ORGANIZATION<|>Conivaptán is another vasopressin receptor antagonist used to treat hyponatremia, helping to correct sodium levels in the blood.)\n##\n(\"relationship\"<|>HIPONATREMIA<|>INSUFICIENCIA CARDIACA<|>Hiponatremia can occur as a complication of insuficiencia cardiaca due to fluid retention and other factors<|>7)\n##\n(\"relationship\"<|>FUROSEMIDA<|>HIPONATREMIA<|>Furosemida is used as a treatment for hiponatremia to help remove excess fluid and correct sodium levels<|>8)\n##\n(\"relationship\"<|>ALBUMINA<|>INSUFICIENCIA CARDIACA<|>Albúmina may be administered to patients with insuficiencia cardiaca to help manage fluid retention<|>6)\n##\n(\"relationship\"<|>TOLVAPTÁN<|>HIPONATREMIA<|>Tolvaptán is used to treat hiponatremia by promoting the excretion of free water and correcting sodium levels<|>9)\n##\n(\"relationship\"<|>CONIVAPTÁN<|>HIPONATREMIA<|>Conivaptán is also used to treat hiponatremia, functioning similarly to Tolvaptán<|>9)\n<|COMPLETE|>"}]}